AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT or PET/MRI
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proctoscopy
Description: Undergo proctoscopy
Study NCT04929028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy
Study NCT05682885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic Bypass Supermicrosurgery
Description: Axillary Lymph Node Dissection with Lymphatic Bypass Supermicrosurgery
Study NCT04924660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
Study NCT04924660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV027
Description: TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
Study NCT04924660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study NCT04924660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study NCT06644378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3866288
Description: Administered orally.
Study NCT06644378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3866288
Description: Administered orally.
Study NCT06644378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3866288
Description: Administered IV.
Study NCT06171659 — intervention group
Intervention type: DRUG
Intervention: FDG radiotracer
Description: Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
Study NCT06171659 — intervention group
Intervention type: DEVICE
Intervention: PET/MRI
Description: positron emission tomography and magnetic resonance imaging
Study NCT06171659 — intervention group
Intervention type: DEVICE
Intervention: PET/CT imaging
Description: positron emission tomography and computed tomography imaging
Study NCT06322680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Main pancreatic duct and biliary duct external drainage
Description: Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve.
Study NCT06322680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Main pancreatic duct and biliary duct internal drainage
Description: Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures.
Study NCT06576817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity circuit exercise class - Lower and upper extremity
Description: Exercises performed at high intensity effort in the circuit (8 total) will focus on both the lower extremity (4) and upper extremity (4)
Study NCT06576817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity circuit exercise class - Lower extremity alone
Description: All exercises performed at high intensity effort in the circuit (8 total) will focus on the lower extremity alone
Study NCT05058651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05058651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05058651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05058651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05058651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05058651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05058651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT05058651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05058651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05058651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05058651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT05058651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05058651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05058651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo observation
Study NCT05058651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT05499897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasoud guided interscalene block
Description: Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing
Study NCT05499897 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: general anesthesia
Description: Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
Study NCT06027554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoquinone Mesylate
Description: MitoQ given 20 mg per day for 12 weeks.
Study NCT06027554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule taken every day for 12 weeks.
Study NCT06152627 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard of care voice therapy with novice clinician RTSS-Voice documentation
Description: Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.
Study NCT06152627 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard of care voice therapy with expert clinician RTSS-Voice documentation
Description: Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.
Study NCT04816851 — intervention group
Intervention type: PROCEDURE
Intervention: OZAKI technique
Description: an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
Study NCT05850546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
Study NCT05850546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: guideline-recommended corticosteroid therapy
Study NCT05850546 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroid
Description: guideline-recommended corticosteroid therapy
Study NCT05026320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen gel
Description: 10%, bid for 5 days (final application on morning of Day 6)
Study NCT05026320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac gel
Description: 2.32% bid for 5 days (final application on morning of Day 6)
Study NCT05026320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: bid for 5 days (final application on morning of Day 6)
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality fo Life Questionnaire (FHSI)
Description: Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality fo Life Questionnaire (FHSI)
Description: Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vioscreen Food Frequency Questionnaire (FFQ)
Description: Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions. Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item. Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses. Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Handouts
Description: Participants will receive educational handouts on diet.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NutritionCoaching
Description: Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-Up Survey
Description: Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up Survey
Description: Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire
Description: The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire
Description: The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire
Description: Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
Study NCT06050395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire
Description: Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
Study NCT04893278 — intervention group
Intervention type: OTHER
Intervention: Virtual reality
Description: Use of Virtual reality goggles during procedure
Study NCT04605549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107 2 mg dosing
Description: One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
Study NCT04605549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107 4 mg dosing
Description: Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
Study NCT04605549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107 8 mg dosing
Description: Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
Study NCT05626153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine anesthesia care
Description: • Implementing anesthesia management according to current routine practice.
Study NCT05626153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved anesthesia care
Description: * Encourage regional anesthesia or combined regional-general anesthesia.~* Encourage goal-directed fluid therapy, lung-protective ventilation, and active warming during surgery.~* Encourage extubation in the operating room at the end of surgery.~* Encourage multimodal analgesia after surgery.~* Encourage strict indication for ICU admission after surgery.
Study NCT06287515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Given by Radiation Therapy
Study NCT06346691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxofylline
Description: Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
Study NCT06346691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procaterol
Description: Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
Study NCT05889143 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe/Rosuvastatin
Description: Patient treated with Crezet Tablet
Study NCT05792280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI system
Description: Patients will undergo EUS examination with the assistance of AI system.
Study NCT06427005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 5 mg daily for 14 days followed by a 7-day break
Study NCT06427005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 80-120 mg daily for 14 days, followed by a 7-day break
Study NCT06427005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed
Description: raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg
Study NCT05857384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHL42X
Description: IHL-42X consists of acetazolamide and dronabinol.
Study NCT05857384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide 250 MG
Description: A solid tablet containing 250 mg acetazolamide
Study NCT05857384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol 2.5 MG
Description: A soft gelatin capsules containing 2.5mg dronabinol
Study NCT06343649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual
Description: Delivery of images to conduct several exercises of Explicit Motor Imagery
Study NCT06343649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory
Description: Delivery of audio recordings to conduct several exercises of Explicit Motor Imagery
Study NCT06286397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Clascoterone
Description: Application of 1% clascoterone cream twice daily to affected area for 12 weeks.
Study NCT06286397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Application of a vehicle cream to the natal cleft twice daily for 12 weeks
Study NCT04593277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Mobile Technology
Description: Use INSPIRE mobile application
Study NCT04593277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Access to a study-specific control website
Study NCT04593277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04593277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04593277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive telehealth stepped care
Study NCT04593277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive printed SCP materials
Study NCT05373862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter
Description: Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).
Study NCT05878860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATSN-201
Description: AAV.SPR-hGRK1-hRS1syn
Study NCT06475846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5580
Description: HRS5580; low dose
Study NCT06263283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: session of Kine-Yoga
Description: Daily performance of a Kine-Yoga-PEP intervention supervised by a physiotherapist of the department trained in the Kine-Yoga-PEP intervention at J2, J3 and J4 of uterovaginal brachytherapy.~Possibility for the patient to practice this session in autonomy (using PEP tools given to the Shared Educational Check-up) according to her wish during the duration of the treatment and up to 15 days post treatment